At the close of day two of bidding, the issue of Mankind Pharma was overall subscribed 87 per cent, with strong bidding from QIB and NII investors, whose quota sailed through.
A majority of the brokerage firms are positive on the issue and suggest investors subscribe to the issue on a long-term basis but some analysts have raised red flags over rich valuations and the complete OFS nature.